Skip to content
OpenCapital
Get started

Catalyst Pharmaceutical CPRX EV / EBITDA

EV / EBITDA at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
86.6×+82.7×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
38.4×+27.9×
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
1,820.6×—
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
16.4×-5.2×
TG Therapeutics logo
TG TherapeuticsTGTX
37.5×-67.9×
Arrowhead Research logo
Arrowhead ResearchARWR
27.4×—

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K—
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%
Enterprise value$3.09B-4.1%
P/E17.4×-1.6×
P/S6.4×-0.6×

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0×0.0×
Current ratio7.1×+1.0×

Where this comes from

Calculated from Catalyst Pharmaceutical’s reported figures.

enterprise value/ebitda=7.4×

Based on the most recent quarter.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's EV / EBITDA?
Catalyst Pharmaceutical (CPRX) reported EV / EBITDA of 7.4× in Q1 2026.
How has Catalyst Pharmaceutical's EV / EBITDA changed year-over-year?
Catalyst Pharmaceutical's EV / EBITDA decreased by 15.6% year-over-year, from 8.8× to 7.4×.
What is the long-term trend for Catalyst Pharmaceutical's EV / EBITDA?
Over 5 years (2020 to 2025), Catalyst Pharmaceutical's EV / EBITDA has grown at a 7.2% compound annual growth rate (CAGR), from 5.2× to 7.3×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.